A groundbreaking approach to combatting one of the deadliest childhood brain cancers has emerged from the laboratories of Johns Hopkins Kimmel Cancer Center. Researchers have identified a novel therapeutic avenue that disrupts the energy metabolism within tumor cells of group 3 medulloblastoma, potentially heralding a new era in the treatment of this aggressive pediatric malignancy. Utilizing murine models, this work elucidates how the cancer cells reprogram their metabolic pathways to sustain rapid growth and how therapeutic intervention targeting these pathways can significantly curtail tumor progression.
Medulloblastoma represents the most common malignant pediatric brain tumor, and group 3 medulloblastomas are notorious for their dismal prognosis and resistance to conventional therapies. The newly published research in Acta Neuropathologica Communications unpacks the molecular intricacies underlying the tumor’s altered metabolic states. It reveals that the cancer cells substantially increase their oxygen consumption and bioenergetic output, a metabolic rewiring which supports their relentless proliferation.
Central to this metabolic enhancement is a non-coding RNA molecule, lnc-HLX-2-7. Unlike traditional genes encoding proteins, this long non-coding RNA binds directly to DNA, enhancing the expression of the HLX gene. HLX, in turn, acts as a master regulator, upregulating downstream genes that drive tumor cell growth and survival, effectively fueling the cancer’s expansion.
In their earlier study published in Cell Reports in 2024, the Johns Hopkins team demonstrated that targeting lnc-HLX-2-7 with serum oxide nanoparticle-mediated delivery systems substantially diminished tumor volume in mouse models. This nano-delivery system specifically blocks lnc-HLX-2-7 from engaging its DNA target, consequently downregulating HLX expression and disrupting the metabolic programs necessary for tumor viability.
The latest investigation delves deeper into the mechanisms by which this RNA-targeted therapy modulates tumor cell metabolism. Experimental data indicated that lnc-HLX-2-7 actively boosts mitochondrial respiration and ATP production, thereby sustaining the energetic requirements of rapidly dividing tumor cells. By inhibiting lnc-HLX-2-7, researchers effectively starve these cells of oxygen and energy resources, triggering apoptotic pathways and reducing tumor mass.
Building upon these insights, the research group explored a small molecule inhibitor, IACS-010759, which targets mitochondrial complex I, a critical enzyme in the electron transport chain responsible for cellular respiration. By impairing the tumor’s mitochondrial function, IACS-010759 diminishes energy production capabilities, subsequently slowing tumor growth in the animal models studied.
This pharmacological approach is particularly promising as IACS-010759 has already shown efficacy in early-phase clinical trials for other solid tumors and hematologic malignancies. Its ability to interfere with cellular metabolism without extensive toxicity is pivotal in treating brain tumors, where therapy delivery is hampered by the blood-brain barrier.
The challenge of crossing the blood-brain barrier, a formidable obstacle in neuro-oncology, is addressed in this research through the development of small molecules like IACS-010759 that possess the physicochemical properties required for brain penetration. This breakthrough could pave the way for metabolically targeted therapies in pediatric brain cancers, a realm that has seen limited advancement until now.
Furthermore, these findings underscore the broader concept that cancer metabolism is not merely a byproduct of tumorigenesis but a viable and potent target for therapeutic development. By exploiting the unique metabolic dependencies of group 3 medulloblastoma cells, these interventions present the prospect of a highly selective and effective treatment strategy.
The implications of this research extend beyond medulloblastoma, as it contributes to the growing paradigm shift toward metabolism-based cancer therapies. Incorporating metabolic inhibitors in pediatric oncology could complement existing treatment modalities, potentially reducing the need for high-dose chemotherapy or radiation and mitigating long-term adverse effects.
Senior author Dr. Ranjan Perera emphasizes the critical need for innovative therapies targeting metabolic vulnerabilities, noting that this strategy could transform the clinical landscape for children afflicted with these lethal tumors. The integration of genetic, molecular, and metabolic profiling within personalized medicine frameworks may further refine and enhance therapeutic outcomes.
In summary, the Johns Hopkins study represents a major advance in understanding and treating group 3 medulloblastoma by targeting tumor-specific metabolic reprogramming. The convergence of RNA biology, nanotechnology, and metabolic drugs forms a promising triad for developing next-generation, brain-penetrant therapies designed to improve survival and quality of life for affected children.
Subject of Research: Metabolic reprogramming and therapeutic targeting of group 3 medulloblastoma in pediatric brain cancer.
Article Title: Not explicitly provided in the source content.
News Publication Date: March 19, 2026.
Web References:
- Johns Hopkins Kimmel Cancer Center: https://www.hopkinsmedicine.org/kimmel-cancer-center
- Study in Acta Neuropathologica Communications: https://link.springer.com/article/10.1186/s40478-026-02266-2
- Previous study in Cell Reports: https://www.cell.com/cell-reports/fulltext/S2211-1247(24)00266-3
References: Details provided in the links above; includes the latest research articles published by Perera et al.
Image Credits: Johns Hopkins Kimmel Cancer Center; Image by Ranjan Perera, Ph.D.
Keywords: Pediatric brain cancer, group 3 medulloblastoma, tumor metabolism, lnc-HLX-2-7, HLX gene, mitochondrial respiration, IACS-010759, metabolic therapy, blood-brain barrier, RNA-targeted therapy, nanoparticle drug delivery, cancer bioenergetics.
